Open Access
Perspective  |   January 2025
The Landscape of Vascular Endothelial Growth Factor Inhibition in Retinal Diseases
Author Affiliations & Notes
  • Joseph B. Lin
    John F. Hardesty, MD, Department of Ophthalmology and Visual Sciences, Washington University School of Medicine in St. Louis, St. Louis, Missouri, United States
  • Rajendra S. Apte
    John F. Hardesty, MD, Department of Ophthalmology and Visual Sciences, Washington University School of Medicine in St. Louis, St. Louis, Missouri, United States
    Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri, United States
    Department of Developmental Biology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, United States
  • Correspondence: Rajendra S. Apte, John F. Hardesty, MD, Department of Ophthalmology and Visual Sciences, Washington University School of Medicine in St. Louis, 660 S. Euclid Ave, MSC-8096-06-07, St. Louis, MO 63110, USA; [email protected]
Investigative Ophthalmology & Visual Science January 2025, Vol.66, 47. doi:https://doi.org/10.1167/iovs.66.1.47
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Joseph B. Lin, Rajendra S. Apte; The Landscape of Vascular Endothelial Growth Factor Inhibition in Retinal Diseases. Invest. Ophthalmol. Vis. Sci. 2025;66(1):47. https://doi.org/10.1167/iovs.66.1.47.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Ever since the US Food and Drug Administration (FDA) approved the first vascular endothelial growth factor (VEGF) antagonist 2 decades ago, inhibitors of VEGF have revolutionized the treatment of a variety of ocular disorders involving pathologic neovascularization and retinal exudation. In this perspective, we evaluate the current status of anti-VEGF therapies and the real-world challenges encountered with maintaining therapeutic outcomes. Finally, we describe novel VEGF-based and combinatorial approaches that are in clinical development.

Vascular endothelial growth factor (VEGF) inhibitors are the first-line therapy for patients suffering from retinal disorders involving pathologic ocular neovascularization and retinal exudation including in neovascular age-related macular degeneration (AMD) and diabetic retinopathy.1 The initial VEGF-targeting aptamer, pegaptanib, received US Food and Drug Administration (FDA) approval in 2004 but the current VEGF-inhibiting repertoire also includes the monoclonal antibodies bevacizumab, ranibizumab, and brolucizumab; fusion protein aflibercept; and several biosimilars that are currently in clinical development and various stages of approval. Despite the remarkable impact of these VEGF-based therapies for many patients, limitations include subtherapeutic initial response in a minority of patients2 and loss of initial visual acuity gains that is associated with chronic therapy.3,4 The loss of vision related to chronic therapy can be due to atrophy,3 due to subretinal fibrosis,5 or a combination of the two,6 and this can occur despite chronic anti-VEGF pharmacotherapy. Furthermore, the real-world effectiveness of these therapeutics is also hampered by the significant treatment and caregiver burden associated with numerous clinic visits for intravitreal administration of these agents, as well as the associated financial costs and rare risks of treatment-associated complications, including endophthalmitis. There also remains ambiguity regarding the clinical effects of anti-VEGF agents, such as improvements in thickening assessed by optical coherence tomography not always correlating with improvements in visual acuity.1,7,8 These real-world challenges associated with current anti-VEGF therapies have set the stage for the tremendous interest and opportunities to explore novel therapeutic options that may augment the significant gains associated with anti-VEGF therapies. 
Novel VEGF-Targeting Approaches
Vascular Endothelial Growth Factor-C/D
All of the current therapies target VEGF-A, although aflibercept also targets VEGF-B and placental growth factor (PlGF). Currently, therapeutics in development also inhibit VEGF-C or VEGF-D (see Table 1) that have been shown to be activated as a compensatory response to VEGF-A inhibition in the eye as well as in other contexts, such as tumorigenesis.912 Inhibition of these compensatory VEGF pathways may offer more durable angiogenesis-suppressing outcomes. IBI333 is a recombinant bispecific fusion protein that targets both VEGF-A and VEGF-C (NCT05639530). OPT-302 is a VEGF-C/D inhibitor and is currently being evaluated in phase III trials in conjunction with either aflibercept (COAST/NCT04757636) or ranibizumab (ShORe/NCT04757610). These new VEGF-targeting therapies with extended spectrum of action against several VEGF family proteins may offer a more durable clinical response, especially for patients that may have a suboptimal response to currently approved therapies. 
Tyrosine Kinase Inhibitors
The VEGF receptors responsible for VEGF's angiogenic effects are tyrosine kinase receptors. Tyrosine kinase inhibitors offer broad inhibition of all VEGF receptors 1 to 3, potentially providing more durable action beyond targeted VEGF-A inhibition. Tyrosine kinase inhibitors also have the potential to inhibit non-VEGF receptors, such as platelet-derived growth factor receptor (axitinib,13 AIV007,14 D-4517.2,15 sunitinib,15 and EYP-190115) and fibroblast growth factor receptor (AIV00714). OTX-TKI, an axitinib implant, is being studied in phase III trials with aflibercept as a comparator (NCT06495918 and NCT06223958). Two other axitinib extended-release formulations are in phase I or II testing: CLS-AX (ODYSSEY/NCT05891548) and AR-14034 SR (NOVA-1/NCT05769153). AIV007 is a lenvatinib formulation in phase I testing (NCT05698329). GB-102, a sunitinib formulation, completed phase II testing in 2021 (ALTISSIMO/NCT03953079). EYP-1901 is a tyrosine kinase inhibitor currently in phase II testing (VERONA/NCT06099184, DAVIO2/NCT05381948, and NCT05383209). D-4517.2 is a hydroxyl dendrimer therapy administered subcutaneously that can specifically target choroidal neovascular lesions to inhibit tyrosine kinase receptors and is also in phase II testing (Tejas/NCT05387837). 
Topical Delivery
There are several topical delivery systems in development to offer anti-VEGF therapies in more simplified, patient-centered regimens (see Table 1). Previous testing of topical tyrosine kinase inhibitors pazopanib16 and regorafenib17 failed to demonstrate clinical efficacy likely given poor bioavailability of these therapeutics at the sites of choroidal neovascularization (CNV). Despite these prior failed trials, interest in topical anti-VEGF agents remains high. MG-O-1002 is a topical anti-VEGF agent in phase II testing (NCT05390840). KHK4951 is a topical tyrosine kinase inhibitor (tivozanib) formulation also in phase II testing (NCT06116890 and NCT06116916). EXN407 is a topical drug that inhibits splicing of VEGF transcript by targeting serine/arginine-rich protein-specific kinase 1.18 EXN407 has completed phase I and phase II testing (NCT04565756). 
Gene Therapies
Gene therapies can induce the expression of anti-VEGF molecules in native ocular cells, such as the retinal pigment epithelium to offer more durable VEGF inhibition as compared with current molecules delivered by intravitreal injection. The majority of these therapeutics utilize adeno-associated viral vectors to deliver gene therapies, but lentiviral and CRISPR/Cas methodologies can also be employed. Some gene therapeutics that are under current clinical testing are: LX102 in phase I and phase II testing (NCT06198413, NCT05831007, and VENUS/NCT06196840), ADVM-022 in phase II testing (LUNA/NCT05536973, INFINITY/NCT04418427, OPTIC-EXT/NCT04645212, and INFINITY-EXT/NCT05607810), SKG0106 in phase I and phase II testing (NCT06213038, NCT05986864, NCT06237777, and NCT06346600), RRG001 in phase I and phase II testing (NCT06141460 and NCT06412224), EXG102-031 in phase I and phase II testing (NCT06183814 and Everest/NCT05903794), FT-003 in phase I and phase II testing (NCT06492876 and NCT06492863), KH658 in phase I and phase II testing (NCT06458595), KH631 in phase I and phase II testing (NCT05657301 and NCT05672121), RGX-314 in phase II and phase III testing (AAVIATE/NCT04514653, ASCENT/NCT05407636, ATMOSPHERE/NCT04704921, ALTITUDE/NCT04567550, and SRLTFU/NCT03999801), 4D-150 in phase I and phase II testing (NCT05197270 and NCT05930561), HG202 in early phase I testing (SIGHT-I/NCT06031727), ABI-110 in phase I and phase II testing (NCT06550011), BD311 in early phase I testing (NCT05099094), and LX109 (NCT06022744). 
Drug Targets Beyond VEGF
Suboptimal visual gains and the subtherapeutic response associated with chronic VEGF targeted therapies suggests that there may be VEGF-independent pathways involved in neovascular AMD offering novel therapeutic opportunities. In the following section, we summarize some of the main drug targets under clinical investigation (delineated in  Table 2). 
Table 1.
 
Novel VEGF-Targeting Therapeutics in Clinical Development for Neovascular AMD or Diabetic Macular Edema Since September 2019
Table 1.
 
Novel VEGF-Targeting Therapeutics in Clinical Development for Neovascular AMD or Diabetic Macular Edema Since September 2019
Table 2.
 
Non-VEGF Drug Targets in Clinical Development for Neovascular AMD or Diabetic Macular Edema Since September 2019
Table 2.
 
Non-VEGF Drug Targets in Clinical Development for Neovascular AMD or Diabetic Macular Edema Since September 2019
Angiopoietin
Faricimab received FDA approval in 2022, which, unlike previous anti-VEGF agents, is a bispecific inhibitor that also targets angiopoietin 2. Activation of the angiopoietin pathway is thought to stabilize neovascular lesions and desensitize the effects of VEGF. In the phase III clinical trials (YOSEMITE/NCT03622580, RHINE/NCT03622593, TENAYA/NCT03823287, and LUCERNE/NCT03823300), faricimab demonstrated similar clinical efficacy to aflibercept.1922 Although clinical trial results indicated that patients treated with faricimab could be extended to longer inter-injection intervals, it remains unclear whether dual inhibition of VEGF and angiopoietin 2 offers more durable anti-neovascular effects as compared with current anti-VEGF monotherapies which were not administered in a treat-and-extend protocol in clinical trials. This is also similar to clinical trials of high dose aflibercept (8 mg)23 in which the comparator—aflibercept (2 mg)—was administered at a fixed dosing interval. The comparator does not reflect current clinical practice as most providers use treat-and-extend regimens as the neovascular lesions stabilize on clinical examination and imaging.24 As such, the claim of increased inter-treatment interval for these clinical trial designs may need further evaluation.21 Nonetheless, angiopoietin remains a therapeutic target of high interest. Three additional drugs that, like faricimab, target both VEGF and angiopoietin 2 (ASKG712/AM712, zifibancimig, and BI 836880) are in phase I or II clinical testing (see Table 2). Angiopoietin 2 is an inhibitor of angiopoietin 1 receptor; thus, an alternative strategy would be to activate the angiopoietin 1 receptor directly. AXT107 and PMC-403 are angiopoietin 1 receptor agonists currently in phase I or II testing (see Table 2). 
Fibroblast Growth Factors
Fibroblast growth factors (FGFs) encompass a family of signaling ligands that regulate the endothelial cell response to pro-angiogenic cues.25 Preclinical studies demonstrated that specifically FGF2 is an essential ligand promoting CNV,2628 although other FGF ligands may also have a role.29 Some of these studies have indicated that targeting both FGF2 and VEGF can inhibit endothelial cell sprouting beyond that achieved by VEGF inhibition alone.28 Two therapeutics targeting FGF2—RBM-007 and RC-28E—are currently in either phase II or III testing (see Table 2). 
Integrins
Integrins are ubiquitously expressed cell surface receptors that mediate cellular adhesion to other cells and to the extracellular matrix. Integrins mediate a wide variety of cellular processes, including motility, proliferation, apoptosis, and survival. Notably, integrins may also regulate the recruitment of peripheral immune cells to the eye in AMD and their activation in situ to angiogenesis-modulating phenotypes.30 AG-73305 is a bispecific fusion protein that targets integrins and VEGF, and it is in phase II testing (see Table 2). OCU200 is a fusion protein of tumstatin and transferrin, of which the former targets VEGF and integrins. It is in phase I testing (see Table 2). 
Complement
Complement inhibition has long been an attractive therapeutic avenue in the treatment of AMD, spurred by foundational pathologic,31,32 genetic,3341 and other preclinical studies demonstrating that complement inhibition reduces CNV in animal models.42,43 These research efforts have come to clinical fruition in 2023 with the C3 inhibitor pegcetacoplan and the C5-inhibiting aptamer avacincaptad pegol both receiving FDA approval for the treatment of geographic atrophy (GA) secondary to non-exudative AMD.44 Although the FDA-approved complement inhibitors both decreased the progression of GA in clinical trials, they were associated with an increased risk for conversion to neovascular AMD with clinical trial data suggesting an approximately 1.5 to 6.5-fold increase in the development of neovascular AMD.45,46 Although this somewhat mirrors the atrophic retinal neurodegeneration that has been associated with chronic anti-VEGF therapies,47,48 further studies are necessary to determine the etiology of increased risk of exudation following therapy with complement inhibitors. There is significant interest in targeting complement in the treatment of neovascular AMD as well. Iptacopan, an oral factor B inhibitor, is in phase II testing (see Table 2). IBI302, a bispecific fusion protein targeting VEGF and the complement cascade, is in phase III testing (see Table 2). Preclinical studies have demonstrated a role for complement proteins in regulating CNV,43 highlighting the importance of understanding the relationship among complement proteins, VEGF, and CNV. 
Targeting Senescence
With age, senescent cells accumulate in multiple tissues and persistently secrete inflammatory mediators which is thought to promote age-related dysfunction in a variety of organ systems.4951 Preclinical studies have demonstrated that senescence and senescence associated secretory proteins (SASPs) may represent a common cellular endpoint of various ocular pathologies, including following microvascular ischemia in diabetic retinopathy.52,53 Recently, preclinical studies have also linked intracellular cholesterol accumulation to macrophage and photoreceptor senescence via depleting NAD+,5457 providing a possible mechanistic link between the lipid-rich drusen pathognomonic for early stage AMD and retinal neurodegeneration in late stage non-exudative AMD. Taken together, these studies have provided the foundational scientific impetus for targeting senescent cells as a possible therapy for dry AMD. There is also a possible role for cellular senescence in neovascular AMD due upregulation of inflammatory and pro-angiogenic factors and impaired autophagy.58 Nonetheless, the senolytic drug UBX1325 was unable to demonstrate noninferiority compared to aflibercept in the treatment of neovascular AMD (ENVISION/NCT05275205). However, significant interest remains in senolytic therapy for diabetic macular edema for which phase II testing is ongoing59 (ASPIRE/NCT06011798). 
Inflammatory Signaling
There is abundant basic science and clinical evidence that the immune system plays an important role in the pathogenesis of neovascular AMD.56,6072 Pathologic studies of AMD eyes indicates that ocular immune privilege is breached in both nonexudative and neovascular AMD with accumulation of immune cells, especially macrophages, near sites of drusen and neovascularization.6268 The exact function of these accumulated immune cells in promoting or inhibiting the disease process remains ambiguous. It is likely that immune cell ontogeny, activation state, age-related dysfunction, or other yet-unknown factors contribute to whether immune cells promote or inhibit ocular neovascularization.30,70,73 For example, early preclinical studies demonstrated that macrophage depletion reduced the severity of angiogenesis in animal models of disease.74,75 These seminal studies were corroborated by more recent studies demonstrating that there are specific macrophage subclasses that promote angiogenesis.73,76,77 The macrophage activation state, driven by interactions with the local ocular milieu, also plays a key role, with proinflammatory macrophages (i.e. M1-like) thought to be anti-angiogenic.30,70 Despite this ambiguity, several chemokine- or cytokine-targeting therapeutics are under study including those aimed at the CXC chemokine receptor 3 and interleukin 6 (see Table 2). 
Wnt Signaling
Wnt signaling is a highly conserved pathway important for a wide variety of developmental processes.78 Several studies have pointed to increased activation of Wnt signaling in AMD,7984 although whether this activation is a protective or pathologic mechanism is unknown. It is likely that the role of Wnt signaling is multifaceted and may have different disease roles in a ligand-, cell-, and context-dependent manner. EYE103 is a trispecific Wnt agonist and is in phase II and III testing (AMARONE/NCT05919693 and BRUNELLO/NCT06571045). 
Conclusions
For the past 2 decades, VEGF inhibition has served as the mainstay of treating various forms of ocular neovascularization and edema and will likely remain a cornerstone of the retinal specialist's therapeutic armamentarium for many decades to come. In this perspective, we have summarized novel therapeutic targets in neovascular AMD other than VEGF. The major challenges with chronic VEGF antagonists remain treatment burden, under-responsiveness in some patients, risk of endophthalmitis, loss of initial visual gains with long term therapy due to atrophy and fibrosis, and a ceiling effect on efficacy. Given the wide variety of novel compounds currently in clinical development, it remains unclear which—if any—of these novel drug targets offer clinical effects independent of and synergistic with VEGF inhibition. For example, the ENVISION trial failed to demonstrate that the senolytic UBX1325 monotherapy was noninferior to aflibercept for the treatment of neovascular AMD. On the other hand, for diabetic macular edema, the BEHOLD trial showed that UBX1325 increased the median time to rescue anti-VEGF treatment by >30 weeks as compared with sham injections highlighting that non-VEGF drug targets may augment the durability of existing anti-VEGF monotherapy. Many therapies in clinical development are being tested in combination with VEGF inhibition, such as the bispecific therapies targeting angiopoietin, complement, fibroblast growth factor, integrins, or interleukin 6 in addition to VEGF inhibition (see Table 2). 
Despite the successes of anti-VEGF monotherapy, the stage has been set for the discovery and development of pathways to be targeted. Preclinical studies continue to identify novel cellular, metabolic, and molecular pathways that could play a role in the development of inappropriate ocular neovascularization,8589 as well as novel therapeutic approaches.90 Even now, the FDA approval of non-VEGF-targeting therapeutics has provided early clues that we must proceed with caution especially because these therapies may influence VEGF drive and the initiation of neovascular disease in previously non-exudative cases. New compounds, if used in combination with VEGF antagonists, must demonstrate short- and long-term superiority and comparable safety. Elucidating the complex interplay between VEGF and novel drug targets and how their potential synergism alters the pathogenesis of AMD—both non-exudative and neovascular—is within reach. 
Acknowledgments
R.S.A. is supported by the Jeffrey T. Fort Innovation Fund, Siteman Retina Research Fund, Starr Foundation, Research to Prevent Blindness/American Macular Degeneration Foundation Catalyst Award for Innovative Research Approaches for Age-Related Macular Degeneration, and an unrestricted grant to the John F. Hardesty, MD, Department of Ophthalmology and Visual Sciences from Research to Prevent Blindness. 
Disclosure: J.B. Lin, None; R.S. Apte, is a cofounder of Metro Biotech (O) and Mobius Scientific (O), and is an advisor to Delavie Sciences (C) and Metro Biotech (C), which are subsidiaries of EdenRoc Sciences, Roche, New Amsterdam Pharma, and QBioMed, RSA's employer Washington University (E) has intellectual property filings and patents issued that have R. S. Apte listed as an inventor 
References
Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell. 2019; 176(6): 1248–1264. [CrossRef] [PubMed]
Bressler SB, Ayala AR, Bressler NM, et al. Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment. JAMA Ophthalmol. 2016; 134(3): 278–285. [CrossRef] [PubMed]
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Maguire MG, Martin DF, et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016; 123(8): 1751–1761. [CrossRef] [PubMed]
Bhisitkul RB, Desai SJ, Boyer DS, Sadda SR, Zhang K. Fellow eye comparisons for 7-year outcomes in ranibizumab-treated AMD subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study). Ophthalmology. 2016; 123(6): 1269–1277. [CrossRef] [PubMed]
Lindenberg S, Nittala MG, Verma A, et al. Subretinal hyperreflective material in regions of atrophy and fibrosis in eyes with neovascular age-related macular degeneration. Can J Ophthalmol. Published online ahead of print May 27, 2024:S0008-4182(24)00135-2, doi:10.1016/j.jcjo.2024.05.007.
Cohen SY, Oubraham H, Uzzan J, Dubois L, Tadayoni R. Causes of unsuccessful ranibizumab treatment in exudative age-related macular degeneration in clinical settings. Retina. 2012; 32(8): 1480–1485. [CrossRef] [PubMed]
Apte RS. Age-related macular degeneration. N Engl J Med. 2021; 385(6): 539–547. [CrossRef] [PubMed]
Sene A, Chin-Yee D, Apte RS. Seeing through VEGF: innate and adaptive immunity in pathological angiogenesis in the eye. Trends Mol Med. 2015; 21(1): 43–51. [CrossRef] [PubMed]
Cabral T, Lima LH, Mello LGM, et al. Bevacizumab injection in patients with neovascular age-related macular degeneration increases angiogenic biomarkers. Ophthalmol Retina. 2018; 2(1): 31–37. [CrossRef] [PubMed]
Li D, Xie K, Ding G, et al. Tumor resistance to anti-VEGF therapy through up-regulation of VEGF-C expression. Cancer Lett. 2014; 346(1): 45–52. [CrossRef] [PubMed]
Grau S, Thorsteinsdottir J, von Baumgarten L, Winkler F, Tonn JC, Schichor C. Bevacizumab can induce reactivity to VEGF-C and -D in human brain and tumour derived endothelial cells. J Neurooncol. 2011; 104(1): 103–112. [CrossRef] [PubMed]
Fan F, Samuel S, Gaur P, et al. Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration. Br J Cancer. 2011; 104(8): 1270–1277. [CrossRef] [PubMed]
Siedlecki J, Wertheimer C, Wolf A, et al. Combined VEGF and PDGF inhibition for neovascular AMD: anti-angiogenic properties of axitinib on human endothelial cells and pericytes in vitro. Graefes Arch Clin Exp Ophthalmol. 2017; 255(5): 963–972. [CrossRef] [PubMed]
Wei X, Zhang T, Yao Y, et al. Efficacy of Lenvatinib, a multitargeted tyrosine kinase inhibitor, on laser-induced CNV mouse model of neovascular AMD. Exp Eye Res. 2018; 168: 2–11. [CrossRef] [PubMed]
Bakri SJ, Lynch J, Howard-Sparks M, Saint-Juste S, Saim S. Vorolanib, sunitinib, and axitinib: a comparative study of vascular endothelial growth factor receptor inhibitors and their anti-angiogenic effects. PLoS One. 2024; 19(6): e0304782. [CrossRef] [PubMed]
Csaky KG, Dugel PU, Pierce AJ, et al. Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration. Ophthalmology. 2015; 122(3): 579–588. [CrossRef] [PubMed]
Joussen AM, Wolf S, Kaiser PK, et al. The Developing regorafenib eye drops for neovascular age-related macular degeneration (DREAM) study: an open-label phase II trial. Br J Clin Pharmacol. 2019; 85(2): 347–355. [CrossRef] [PubMed]
Gammons MVR, Dick AD, Harper SJ, Bates DO. SRPK1 inhibition modulates VEGF splicing to reduce pathological neovascularisation in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2013; 54(8): 5797–5806. [CrossRef] [PubMed]
Wykoff CC, Abreu F, Adamis AP, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022; 399(10326): 741–755. [CrossRef] [PubMed]
Wong TY, Haskova Z, Asik K, et al. Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials. Ophthalmology. 2024; 131(6): 708–723. [CrossRef] [PubMed]
Khanani AM, Kotecha A, Chang A, et al. TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology. Published online ahead of print February 19, 2024:S0161-6420(24)00134-9, doi:10.1016/j.ophtha.2024.02.014.
Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022; 399(10326): 729–740. [CrossRef] [PubMed]
Lanzetta P, Korobelnik JF, Heier JS, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024; 403(10432): 1141–1152. [CrossRef] [PubMed]
Chin-Yee D, Eck T, Fowler S, Hardi A, Apte RS. A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. Br J Ophthalmol. 2016; 100(7): 914–917. [CrossRef] [PubMed]
Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015; 4(3): 215–266. [CrossRef] [PubMed]
Dong Z, Santeford A, Ban N, et al. FGF2-induced STAT3 activation regulates pathologic neovascularization. Exp Eye Res. 2019; 187: 107775. [CrossRef] [PubMed]
Oladipupo SS, Smith C, Santeford A, et al. Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis. Proc Natl Acad Sci U S A. 2014; 111(37): 13379–13384. [CrossRef] [PubMed]
Stahl A, Paschek L, Martin G, Feltgen N, Hansen LL, Agostini HT. Combinatory inhibition of VEGF and FGF2 is superior to solitary VEGF inhibition in an in vitro model of RPE-induced angiogenesis. Graefes Arch Clin Exp Ophthalmol. 2009; 247(6): 767–773. [CrossRef] [PubMed]
Zhang C, Han M, Wu S. Silencing fibroblast growth factor 7 inhibits krypton laser-induced choroidal neovascularization in a rat model. J Cell Biochem. 2019; 120(8): 13792–13801. [CrossRef] [PubMed]
Lin JB, Santeford A, Colasanti JJ, et al. Targeting cell-type-specific, choroid-peripheral immune signaling to treat age-related macular degeneration. Cell Rep Med. 2024; 5(1): 101353. [CrossRef] [PubMed]
Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol. 2002; 134(3): 411–431. [CrossRef] [PubMed]
Loyet KM, Deforge LE, Katschke KJ, et al. Activation of the alternative complement pathway in vitreous is controlled by genetics in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2012; 53(10): 6628–6637. [CrossRef] [PubMed]
Edwards AO, Ritter R, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science. 2005; 308(5720): 421–424. [CrossRef] [PubMed]
Hageman GS, Hancox LS, Taiber AJ, et al. Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: characterization, ethnic distribution and evolutionary implications. Ann Med. 2006; 38(8): 592–604. [CrossRef]
Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005; 308(5720): 385–389. [CrossRef] [PubMed]
Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005; 308(5720): 419–421. [CrossRef] [PubMed]
Maller JB, Fagerness JA, Reynolds RC, Neale BM, Daly MJ, Seddon JM. Variation in complement factor 3 is associated with risk of age-related macular degeneration. Nat Genet. 2007; 39(10): 1200–1201. [CrossRef] [PubMed]
Yates JRW, Sepp T, Matharu BK, et al. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med. 2007; 357(6): 553–561. [CrossRef] [PubMed]
Seddon JM, Yu Y, Miller EC, et al. Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration. Nat Genet. 2013; 45(11): 1366–1370. [CrossRef] [PubMed]
Spencer KL, Hauser MA, Olson LM, et al. Protective effect of complement factor B and complement component 2 variants in age-related macular degeneration. Hum Mol Genet. 2007; 16(16): 1986–1992. [CrossRef] [PubMed]
Gold B, Merriam JE, Zernant J, et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet. 2006; 38(4): 458–462. [CrossRef] [PubMed]
Toomey CB, Kelly U, Saban DR, Bowes Rickman C. Regulation of age-related macular degeneration-like pathology by complement factor H. Proc Natl Acad Sci U S A. 2015; 112(23): E3040–E3049. [CrossRef] [PubMed]
Bora PS, Sohn JH, Cruz JMC, et al. Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. J Immunol. 2005; 174(1): 491–497. [CrossRef] [PubMed]
Wilke GA, Apte RS. Complement regulation in the eye: implications for age-related macular degeneration. J Clin Invest. 2024; 134(9): e178296. [CrossRef] [PubMed]
Heier JS, Lad EM, Holz FG, et al. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet. 2023; 402(10411): 1434–1448. [CrossRef] [PubMed]
Patel SS, Lally DR, Hsu J, et al. Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial. Eye (Lond). 2023; 37(17): 3551–3557. [CrossRef] [PubMed]
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Writing Committee, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2020; 127(4S): S135–S145. [PubMed]
Saint-Geniez M, Maharaj ASR, Walshe TE, et al. Endogenous VEGF is required for visual function: evidence for a survival role on Müller cells and photoreceptors. PLoS One. 2008; 3(11): e3554. [CrossRef] [PubMed]
Coppé JP, Patil CK, Rodier F, et al. Senescence-Associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008; 6(12): e301. [CrossRef] [PubMed]
Krtolica A, Campisi J. Cancer and aging: a model for the cancer promoting effects of the aging stroma. Int J Biochem Cell Biol. 2002; 34(11): 1401–1414. [CrossRef] [PubMed]
Krtolica A, Parrinello S, Lockett S, Desprez PY, Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci U S A. 2001; 98(21): 12072–12077. [CrossRef] [PubMed]
Oubaha M, Miloudi K, Dejda A, et al. Senescence-associated secretory phenotype contributes to pathological angiogenesis in retinopathy. Sci Transl Med. 2016; 8(362): 362ra144. [CrossRef] [PubMed]
Crespo-Garcia S, Tsuruda PR, Dejda A, et al. Pathological angiogenesis in retinopathy engages cellular senescence and is amenable to therapeutic elimination via BCL-xL inhibition. Cell Metab. 2021; 33(4): 818–832.e7. [CrossRef] [PubMed]
Terao R, Sohn BS, Yamamoto T, et al. Cholesterol accumulation promotes photoreceptor senescence and retinal degeneration. Invest Ophthalmol Vis Sci. 2024; 65(10): 29. [CrossRef] [PubMed]
Terao R, Lee TJ, Colasanti J, et al. LXR/CD38 activation drives cholesterol-induced macrophage senescence and neurodegeneration via NAD+ depletion. Cell Rep. 2024; 43(5): 114102. [CrossRef] [PubMed]
Sene A, Khan AA, Cox D, et al. Impaired cholesterol efflux in senescent macrophages promotes age-related macular degeneration. Cell Metab. 2013; 17(4): 549–561. [CrossRef] [PubMed]
Ban N, Lee TJ, Sene A, et al. Impaired monocyte cholesterol clearance initiates age-related retinal degeneration and vision loss. JCI Insight. 2018; 3(17): e120824. [CrossRef] [PubMed]
Blasiak J. Senescence in the pathogenesis of age-related macular degeneration. Cell Mol Life Sci. 2020; 77(5): 789–805. [CrossRef] [PubMed]
Crespo-Garcia S, Fournier F, Diaz-Marin R, et al. Therapeutic targeting of cellular senescence in diabetic macular edema: preclinical and phase 1 trial results. Nat Med. 2024; 30(2): 443–454. [CrossRef] [PubMed]
Handa JT, Bowes Rickman C, Dick AD, et al. A systems biology approach towards understanding and treating non-neovascular age-related macular degeneration. Nat Commun. 2019; 10(1): 3347. [CrossRef] [PubMed]
Strunz T, Kiel C, Sauerbeck BL, Weber BHF. Learning from fifteen years of genome-wide association studies in age-related macular degeneration. Cells. 2020; 9(10): E2267. [CrossRef]
Killingsworth MC, Sarks JP, Sarks SH. Macrophages related to Bruch's membrane in age-related macular degeneration. Eye. 1990; 4(4): 613–621. [CrossRef] [PubMed]
Lopez PF, Grossniklaus HE, Lambert HM, et al. Pathologic features of surgically excised subretinal neovascular membranes in age-related macular degeneration. Am J Ophthalmol. 1991; 112(6): 647–656. [CrossRef] [PubMed]
Oh H, Takagi H, Takagi C, et al. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1999; 40(9): 1891–1898. [PubMed]
Seregard S, Algvere PV, Berglin L. Immunohistochemical characterization of surgically removed subfoveal fibrovascular membranes. Graefes Arch Clin Exp Ophthalmol. 1994; 232(6): 325–329. [CrossRef] [PubMed]
Nakamura R, Sene A, Santeford A, et al. IL10-driven STAT3 signalling in senescent macrophages promotes pathological eye angiogenesis. Nat Commun. 2015; 6: 7847. [CrossRef] [PubMed]
Cherepanoff S, McMenamin P, Gillies MC, Kettle E, Sarks SH. Bruch's membrane and choroidal macrophages in early and advanced age-related macular degeneration. Br J Ophthalmol. 2010; 94(7): 918–925. [CrossRef] [PubMed]
Grossniklaus HE, Wilson DJ, Bressler SB, et al. Clinicopathologic studies of eyes that were obtained postmortem from four patients who were enrolled in the submacular surgery trials: SST Report No. 16. Am J Ophthalmol. 2006; 141(1): 93–104. [CrossRef] [PubMed]
Pennesi ME, Neuringer M, Courtney RJ. Animal models of age related macular degeneration. Mol Aspects Med. 2012; 33(4): 487–509. [CrossRef] [PubMed]
Kelly J, Ali Khan A, Yin J, Ferguson TA, Apte RS. Senescence regulates macrophage activation and angiogenic fate at sites of tissue injury in mice. J Clin Invest. 2007; 117(11): 3421–3426. [CrossRef] [PubMed]
Ueta T, Ishihara K, Notomi S, et al. RIP1 kinase mediates angiogenesis by modulating macrophages in experimental neovascularization. Proc Natl Acad Sci U S A. 2019; 116(47): 23705–23713. [CrossRef] [PubMed]
Zandi S, Nakao S, Chun KH, et al. ROCK-isoform-specific polarization of macrophages associated with age-related macular degeneration. Cell Rep. 2015; 10(7): 1173–1186. [CrossRef] [PubMed]
Droho S, Rajesh A, Cuda CM, Perlman H, Lavine JA. CD11c+ macrophages are proangiogenic and necessary for experimental choroidal neovascularization. JCI Insight. 2023; 8(7): e168142. [CrossRef] [PubMed]
Sakurai E, Anand A, Ambati BK, van Rooijen N, Ambati J. Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003; 44(8): 3578–3585. [CrossRef] [PubMed]
Espinosa-Heidmann DG, Suner IJ, Hernandez EP, Monroy D, Csaky KG, Cousins SW. Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003; 44(8): 3586–3592. [CrossRef] [PubMed]
Droho S, Thomson BR, Makinde HM, Cuda CM, Perlman H, Lavine JA. Ocular macrophage origin and heterogeneity during steady state and experimental choroidal neovascularization. J Neuroinflammation. 2020; 17(1): 341. [CrossRef] [PubMed]
Droho S, Voigt AP, Sterling JK, et al. NR4A1 deletion promotes pro-angiogenic polarization of macrophages derived from classical monocytes in a mouse model of neovascular age-related macular degeneration. J Neuroinflammation. 2023; 20: 238. [CrossRef] [PubMed]
Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004; 20: 781–810. [CrossRef] [PubMed]
Tuo J, Wang Y, Cheng R, et al. Wnt signaling in age-related macular degeneration: human macular tissue and mouse model. J Transl Med. 2015; 13: 330. [CrossRef] [PubMed]
Qiu F, Liu Z, Zhou Y, et al. Decreased circulating levels of Dickkopf-1 in patients with exudative age-related macular degeneration. Sci Rep. 2017; 7(1): 1263. [CrossRef] [PubMed]
Zhou T, Hu Y, Chen Y, et al. The pathogenic role of the canonical Wnt pathway in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2010; 51(9): 4371–4379. [CrossRef] [PubMed]
Hu Y, Chen Y, Lin M, Lee K, Mott RA, xing Ma J. Pathogenic role of the Wnt signaling pathway activation in laser-induced choroidal neovascularization. Invest Ophthalmol Vis Sci. 2013; 54(1): 141–154. [CrossRef] [PubMed]
Lin JB, Sene A, Wiley LA, et al. WNT7A/B promote choroidal neovascularization. Exp Eye Res. 2018; 174: 107–112. [CrossRef] [PubMed]
Liu D, Du J, Xie H, et al. Wnt5a/β-catenin-mediated epithelial-mesenchymal transition: a key driver of subretinal fibrosis in neovascular age-related macular degeneration. J Neuroinflammation. 2024; 21(1): 75. [CrossRef] [PubMed]
Almalki WH, Almujri SS. The impact of NF-κB on inflammatory and angiogenic processes in age-related macular degeneration. Exp Eye Res. 2024; 248: 110111. [CrossRef] [PubMed]
Wong JHC, Ma JYW, Jobling AI, et al. Exploring the pathogenesis of age-related macular degeneration: a review of the interplay between retinal pigment epithelium dysfunction and the innate immune system. Front Neurosci. 2022; 16: 1009599. [CrossRef] [PubMed]
Bhatwadekar AD, Kansara V, Luo Q, Ciulla T. Anti-integrin therapy for retinovascular diseases. Expert Opin Investig Drugs. 2020; 29(9): 935–945. [CrossRef] [PubMed]
Terao R, Kaneko H. Lipid signaling in ocular neovascularization. Int J Mol Sci. 2020; 21(13): 4758. [CrossRef] [PubMed]
Van Bergen T, Etienne I, Cunningham F, et al. The role of placental growth factor (PlGF) and its receptor system in retinal vascular diseases. Prog Retin Eye Res. 2019; 69: 116–136. [CrossRef] [PubMed]
Sarkar A, Junnuthula V, Dyawanapelly S. Ocular therapeutics and molecular delivery strategies for neovascular age-related macular degeneration (nAMD). Int J Mol Sci. 2021; 22(19): 10594. [CrossRef] [PubMed]
Table 1.
 
Novel VEGF-Targeting Therapeutics in Clinical Development for Neovascular AMD or Diabetic Macular Edema Since September 2019
Table 1.
 
Novel VEGF-Targeting Therapeutics in Clinical Development for Neovascular AMD or Diabetic Macular Edema Since September 2019
Table 2.
 
Non-VEGF Drug Targets in Clinical Development for Neovascular AMD or Diabetic Macular Edema Since September 2019
Table 2.
 
Non-VEGF Drug Targets in Clinical Development for Neovascular AMD or Diabetic Macular Edema Since September 2019
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×